TRISKELION

ENDOCRINE DISRUPTION ASSESSMENT

Endocrine disruption (ED) is a complex endpoint to assess, but its impact cannot be overlooked. Under REACH, it serves as grounds to consider a substance an SVHC, which opens the door to authorization or restriction.
Under the Biocidal Products Regulation (BRP) and Plant Protection Products Regulation (PPPR), it results in the non-approval/renewal of an active substance.

ED assessments have been a required endpoint for the approval of biocides and plant protection products in the EU since 2018. In order to be considered an ED, a substance has to show three key features: observed adverse effects, an endocrine mode of action and a causal relationship between the two.



DUCARES B.V. | trading as TRISKELION

OUR KNOWLEDGE IS YOUR STRENGTH

www.triskelion.nl

info@triskelion.nl

TRISKELION

ENDOCRINE DISRUPTION ASSESSMENT

TRISKELION can assist you with the complete assessment of ED properties for your products, including:

- Preparing registration/compliance strategies for relevant legislations (e.g. BPR, PPPR, REACH) with an eye on the latest regulatory developments
- Performing a detailed literature search, customized to your needs and available information
- Assessing available data (literature, studies, QSAR data) for ED properties
- Preparing weight-of-evidence approaches to assess the ED potential of a substance
- Reporting available data using the EFSA/ECHA Excel template
- Developing testing strategies for ED data generation
- Study contracting and monitoring of ED-related studies
- Drafting expert statements on ED
- Interacting with other registrants/consortia, authorities and downstream users on the impact of ED

TRISKELION offers testing and consultancy services to clients active in the food, feed, (agro)chemical and pharmaceutical industries. Our goal is to help develop products that improve the health and wellbeing of your customers.

www.triskelion.nl

info@triskelion.nl